MNTA
07:16 MNTA Momenta Pharma upped to $54 from $27 at ThinkEquity (25.56 +2.25) ThinkEquity raises their MNTA tgt to $54 from $27 as they believe MNTA's competitors (TEVA, Amphastar, and others) have little chance of gaining approval (0% probability). They do not believe the competitors have adequately characterized the active ingredients of either Lovenox or their products to satisfy regulatory requirements. Firm believes MNTA, by virtue of its superior polysaccharide characterization technology, may provide the FDA with information sufficient for approval (sole generic, 70% probability).
0 Comments:
Post a Comment
<< Home